University of California, San Francisco
Welcome,         Profile    Billing    Logout  
 19 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kumar, Shaji
ASCENT, NCT03289299: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Active, not recruiting
2
87
US
Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
International Myeloma Foundation, Amgen, Janssen Scientific Affairs, LLC, Celgene, Trevie, Inc.
Smoldering Multiple Myeloma
09/23
11/31
MyDRUG, NCT03732703: Myeloma-Developing Regimens Using Genomics

Checkmark Data from MyDRUG study for MM at ASH 2022
Dec 2022 - Dec 2022: Data from MyDRUG study for MM at ASH 2022
Recruiting
1/2
228
US
Abemaciclib, dexamethasone, ixazomib, pomalidomide, abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst, Enasidenib, dexamethasone, ixazomib, pomalidomide, enasidenib: AG221, IDHIFA, Cobimetinib, dexamethasone, ixazomib, pomalidomide, cobimetinib: Cotellic, GDC-0973, RG7420, Erdafitinib, dexamethasone, ixazomib, pomalidomide, erdafitinib: G-024, JNJ-42756493, JNJ-493, Venetoclax, dexamethasone, ixazomib, pomalidomide, venetoclax: Venclexta: ABT-199, Daratumumab, dexamethasone, ixazomib, pomalidomide, daratumumab: Darzalex, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin: BLENREP, GSK2857916, Selinexor, dexamethasone, ixazomib, pomalidomide, Selinexor: XPOVIO
Multiple Myeloma Research Consortium, AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
02/22
02/24
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
1/2
27
Canada, US
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
08/23
11/23
LUMMICAR STUDY 2, NCT03915184: Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1/2
105
Canada, US
zevor-cel, CAR-BCMA T Cell Infusion
CARsgen Therapeutics Co., Ltd.
Multiple Myeloma
12/24
12/34
NCT05145816: Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Recruiting
1/2
37
US
Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks), Belantamab mafodotin 1.9 mg/kg (12 weeks), Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages, Belantamab mafodotin 1.0 mg/kg (12 weeks)
University of Texas Southwestern Medical Center, GlaxoSmithKline
AL Amyloidosis, Amyloidosis
03/26
09/26
NCT04123418: A Study of WVT078 in Patients With Multiple Myeloma (MM)

Terminated
1
56
Europe, Japan, US, RoW
WVT078, WHG626
Novartis Pharmaceuticals
Multiple Myeloma (MM)
12/24
12/24
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Selby, Van
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
Auerback, Glenna
No trials found

Download Options